BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26448190)

  • 21. BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas.
    Cipriani NA; Letovanec I; Hornicek FJ; Mullen JT; Duan Z; Borger DR; Nielsen GP
    Histopathology; 2014 Apr; 64(5):639-46. PubMed ID: 24117833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
    Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
    Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
    Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
    Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and genetic diversity in the metastatic process of melanoma.
    Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
    J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
    Brocard A; Knol AC; Bossard C; Denis MG; Quéreux G; Saint-Jean M; Peuvrel L; Khammari A; Blancho G; Dantal J; Dréno B
    Acta Derm Venereol; 2017 Apr; 97(4):483-488. PubMed ID: 27868139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
    Romano RC; Carter JM; Folpe AL
    Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
    Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
    Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
    Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
    Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing for
    Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
    J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.